BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 35253277)

  • 1. FOXM1: a new therapeutic target of extramammary Paget disease.
    Ito T; Tanaka Y; Kaku-Ito Y; Oda Y; Nakahara T
    Sci Rep; 2024 Feb; 14(1):4048. PubMed ID: 38374400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KS-EMPD-1: a novel cell line of primary extramammary Paget's disease.
    Ito T; Tanaka Y; Ichiki T; Kaku-Ito Y; Nakahara T
    Hum Cell; 2023 Sep; 36(5):1813-1829. PubMed ID: 37432591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
    Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
    Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
    Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
    Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
    Kang Z; Xu F; Zhang QA; Lin J; Wu Z; Zhang X; Luo Y; Xu J; Guan M
    Mod Pathol; 2012 Aug; 25(8):1160-8. PubMed ID: 22522847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of genetic alterations in extramammary Paget disease using whole exome analysis.
    Kiniwa Y; Yasuda J; Saito S; Saito R; Motoike IN; Danjoh I; Kinoshita K; Fuse N; Yamamoto M; Okuyama R
    J Dermatol Sci; 2019 Apr; 94(1):229-235. PubMed ID: 31023612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-155, a potential serum marker of extramammary Paget's disease.
    Guo H; Qi RQ; Sheng J; Liu C; Ma H; Wang HX; Li JH; Gao XH; Wan YS; Chen HD
    BMC Cancer; 2018 Nov; 18(1):1078. PubMed ID: 30458743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intertumor and intratumor heterogeneity of PIK3CA mutations in extramammary Paget's disease.
    Kusaba Y; Kajihara I; Myangat TM; Tanaka K; Sakamoto R; Maeda-Otsuka S; Yamada-Kanazawa S; Sawamura S; Kanemaru H; Nishimura Y; Nakamura-Kashiwada K; Makino K; Miyashita A; Aoi J; Masuguchi S; Fukushima S
    J Dermatol; 2022 May; 49(5):508-514. PubMed ID: 35253277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome analyses reveal FOXA1 dysregulation in mammary and extramammary Paget's disease.
    Mai R; Zhou S; Zhou S; Zhong W; Hong L; Wang Y; Lu S; Pan J; Huang Y; Su M; Crawford R; Zhou Y; Zhang G
    Hum Pathol; 2018 Jul; 77():152-158. PubMed ID: 29630912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extramammary Paget's Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments.
    Ishizuki S; Nakamura Y
    Curr Oncol; 2021 Aug; 28(4):2969-2986. PubMed ID: 34436026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramammary Paget's Disease: A Review of the Literature Part II: Treatment and Prognosis.
    Morris CR; Hurst EA
    Dermatol Surg; 2020 Mar; 46(3):305-311. PubMed ID: 31688232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramammary Paget's Disease.
    Asel M; LeBoeuf NR
    Hematol Oncol Clin North Am; 2019 Feb; 33(1):73-85. PubMed ID: 30497678
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.